Paclitaxel (PTX), the first-line prostate cancer treatment, was added to polyethyleneimine-functionalized multiple-wall carbon nanotubes (CNTs) by Edson José Comparetti et al. These particles were then coated with PSMA antibodies to target prostate cancer cells. Here, FOLH1 is linked to prostate carcinoma.